ANVS

Annovis Bio, Inc. is a clinical-stage biotechnology company developing novel therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. The company's lead drug candidate targets the toxic proteins that cause neurodegeneration by inhibiting their production rather than clearing them after formation. Annovis's approach addresses multiple neurotoxic proteins simultaneously, including amyloid beta, tau, alpha-synuclein, and TDP43, which are implicated in various neurodegenerative diseases. The company conducts clinical trials evaluating safety and efficacy in Alzheimer's and Parkinson's patients. Annovis Bio's therapeutic approach, if successful, could provide a disease-modifying treatment addressing the underlying causes of neurodegeneration. Founded in 2008 and headquartered in Berwyn, Pennsylvania, Annovis operates in the high-risk, high-reward neuroscience therapeutic space. The company's success depends on clinical trial results, regulatory approvals, and the ability to demonstrate meaningful clinical benefits for patients with neurodegenerative diseases. Annovis competes in a crowded field of companies developing treatments for Alzheimer's and Parkinson's.